Venmax Drugs and Pharmaceuticals Announces Two Key Board Appointments

Venmax drugs & pharmaceuticals Limited has strengthened its board of directors with two strategic appointments announced following a board meeting held on March 30, 2026. The pharmaceutical company disclosed these developments in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Board Appointments Overview

The board meeting, which commenced at 4:00 P.M and concluded at 5:00 P.M on March 30, 2026, resulted in the approval of two key director appointments based on recommendations from the Nomination and Remuneration Committee.

Position	Name	Capacity	Term Details
Additional Director	Mrs. Padmaja Kalyani Sadhanala (DIN: 03096445)	Non-Executive and Non-Independent	Until next EGM/AGM
Additional Director	Mr. Revoor Ramachandra (DIN: 00490051)	Non-Executive and Independent	5 years from March 30, 2026

Director Profile: Mrs. Padmaja Kalyani Sadhanala

Mrs. Padmaja Kalyani Sadhanala brings significant expertise to the board with her Post Graduate qualification in Genetics and Cell Biology. She possesses over 20 years of experience in the pharmaceutical industry, making her well-suited for the company's operations. Notably, she is the spouse of the Managing Director of the company. Her appointment as Additional Director will be effective until the conclusion of the next General or Annual General Meeting, after which she will be eligible for appointment as a regular Director.

Director Profile: Mr. Revoor Ramachandra

Mr. Revoor Ramachandra comes with extensive industrial experience spanning more than 42 years across Defence, Aerospace, and Automotive components industries. His educational background includes a B.E (Mechanical) from B.M.S. College of Engineering and an M.B.A. from Central College, Bangalore, affiliated to Bangalore University, with specialization in Production and Materials Management. He has been appointed for a five-year term as an Independent Director and has no relationship with any existing directors of the company.

Regulatory Compliance and Next Steps

Compliance Aspect	Details
Regulatory Clearance	Both directors are not debarred by SEBI or other regulatory authorities
Managerial Remuneration	Nil for both appointments
Member Approval	Required at next General/Annual General Meeting
Documentation	Disclosures provided as per Regulation 30 requirements

Both appointments are subject to approval by the company's members at the next General or Annual General Meeting. The company has confirmed that neither appointee is debarred from holding director positions by SEBI or any other regulatory authority. No managerial remuneration has been specified for either position at this time.

The appointments reflect the company's commitment to strengthening its governance structure with experienced professionals from relevant industry backgrounds, particularly in pharmaceutical and industrial sectors.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-0.50%	+3.70%	+1.50%	+16.40%	-7.87%	+291.64%

Venmax Drugs and Pharmaceuticals Limited has announced significant modifications to its draft scheme of amalgamation with Hatri Pharma Private Limited, following a board meeting conducted on March 27, 2026. The amendments specifically address changes in the share capital structure of the transferee company.

Board Meeting Outcomes

The board of directors convened on Friday, March 27, 2026, from 2.30 p.m. to 3.30 p.m., to consider and approve amendments to Para 2.2 of the Share Capital Clause in the draft scheme of amalgamation. The meeting was held in continuation of the earlier submission of the draft scheme between Hatri Pharma Private Limited (transferor company) and Venmax Drugs and Pharmaceuticals Limited (transferee company), originally submitted on November 12, 2025.

Share Capital Structure Changes

The key modifications approved by the board involve significant changes to the issued, subscribed and paid-up share capital of the company:

Parameter	Previous Structure	Amended Structure
Authorized Share Capital	2.20 crore equity shares of Rs. 10 each (Rs. 22.00 crores)	2.20 crore equity shares of Rs. 10 each (Rs. 22.00 crores)
Issued, Subscribed & Paid-up Capital	80.07 lakh equity shares of Rs. 10 each (Rs. 8.00 crores)	1.15 crore equity shares of Rs. 10 each (Rs. 11.58 crores)
Convertible Equity Share Warrants Pending	72.56 lakh warrants of Rs. 5 each (Rs. 3.62 crores received)	36.81 lakh warrants of Rs. 5 each (Rs. 1.84 crores received)

Warrant Conversion Details

The company had originally issued 1.00 crore convertible equity share warrants at a price of Rs. 20 per warrant. Out of these, the company has successfully allotted 63.44 lakh equity shares to warrant holders pursuant to conversion of warrants. The remaining 36.81 lakh equity share warrants are still pending conversion.

The exercise of the remaining transferee company warrants by holders would result in further increases to the issued, subscribed and paid-up equity share capital of the company. This conversion mechanism provides flexibility for future capital expansion as warrant holders exercise their conversion rights.

Regulatory Compliance

The disclosure has been made in accordance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015. The modified draft scheme of amalgamation incorporating the approved changes in share capital structure has been duly attached with the regulatory filing.

The company's scrip code on BSE is 531015, and the registered office is located at Sy. No. 1-1-5, Brig Sayeed Road, Hanumanji Colony, Bowenpally, Picket, Hyderabad - 500009.